BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Clinical Trial ID NCT01791478

Rank	Title	Journal	Year	PubWeight™‹?›
1	Luminal breast cancer: from biology to treatment.	Nat Rev Clin Oncol	2013	1.16
2	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.	Pharmgenomics Pers Med	2014	1.09
3	Multidrug-resistant breast cancer: current perspectives.	Breast Cancer (Dove Med Press)	2014	0.99
4	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.	Cancer Discov	2016	0.98
5	PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.	Onco Targets Ther	2016	0.96
6	Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.	World J Clin Oncol	2014	0.95
7	Targeted therapies for ER+/HER2- metastatic breast cancer.	BMC Med	2015	0.91
8	A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.	Clin Cancer Res	2016	0.88
9	Clinical application of high-throughput genomic technologies for treatment selection in breast cancer.	Breast Cancer Res	2013	0.85
10	First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?	J Exp Clin Cancer Res	2016	0.78
11	Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.	Ther Adv Med Oncol	2016	0.75